Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 2019 Earnings Presentation
14 slides from Angiodynamics's earnings presentation, Jul 10, 2019
Slide 1: Fourth Quarter 2019 Earnings Presentation
AngioDynamics Fourth Quarter 2019 Earnings Presentation July 10, 2019 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Fourth Quarter 2019 Highlights
Fourth Quarter 2019 Highlights Financial Performance • Revenue of $96.3 million (+9.0%), compared to $88.3 million a year ago. Organic revenue (excluding RadiaDyne and BioSentry) was $93.0 million (+5.2%). • Gross Margin of 53.6%, flat year over year. • Adjusted EPS of $0.25, compared to $0.20 a yea
Slide 4: Sale of Fluid Management
Sale of Fluid Management Use of Proceeds US GAAP Gain Tax Impact $ in thousands $ in thousands $ in thousands Cash Consideration $169,242 Proceeds Received $169,242 Cash Consideration $169,242 Less: Transaction Costs 4,030 Less: Working Capital Adjustment 612 Less: Transaction Costs 4,030 Less: Work
Slide 5: Fourth Quarter FY 2019 Results (unaudited)
Fourth Quarter FY 2019 Results (unaudited) FY2019 FY2018 FY2019 FY2018 Q4 Results Q4 Results Q4 Results Q4 Results $ in thousands (except per share data) Actual Actual Change Pro Forma Pro Forma Change Revenue $96,300 $88,317 9.0% $71,182 $66,193 7.5% - Vascular Interventions and Therapies 56,206 52
Slide 6: FY 2019 Results (unaudited)
FY 2019 Results (unaudited) FY2019 FY2018 FY2019 FY2018 Results Results Results Results $ in thousands (except per share data) Actual Actual Change Pro Forma Pro Forma Change Revenue $359,484 $344,285 4.4% $270,634 $261,655 3.4% - Vascular Interventions and Therapies 208,751 202,334 3.2% 119,901 119
Slide 7: Driving Future Growth
Driving Future Growth • Net cash balance of ~$85 million plus $125 million credit facility will provide over $175 million of available capital to deploy Internal Investments: External Investments: § Oncology, NanoKnife Platform § M&A and Licensing for acquiring § Thrombus Management, AngioVac innova
Slide 8: FY 2020 Guidance
FY 2020 Guidance Revenue $280m - $286m Adjusted EPS $0.25 - $0.30 Gross Margin 58% - 59% 8
Slide 9: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 9
Slide 10: Reconciliation of GAAP to Non-GAAP Net Income and EPS – Actual
Reconciliation of GAAP to Non-GAAP Net Income and EPS – Actual Actual Actual Three months ended Twelve months ended Amounts in thousands May 31, May 31, May 31, May 31, 2019 2018 2019 2018 (unaudited) (unaudited) Net income $ 58,873 $ 2,102 $ 61,340 $ 16,335 Amortization of intangibles 5,126 4,202 1
Slide 11: Reconciliation of GAAP to Non-GAAP Net Income and EPS – Pro Forma
Reconciliation of GAAP to Non-GAAP Net Income and EPS – Pro Forma Pro Forma Pro Forma Three months ended Twelve months ended Amounts in thousands May 31, May 31, May 31, May 31, 2019 2018 2019 2018 (unaudited) (unaudited) Net income $ 2,753 $ (2,483) $ (11,146) $ (6,227) Amortization of intangibles
Slide 12: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS – Actual
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS – Actual Actual Actual Three months ended Twelve months ended May 31, May 31, May 31, May 31, Amounts in thousands 2019 2018 2019 2018 (unaudited) (unaudited) Net income $ 58,873 $ 2,102 $ 61,340 $ 16,335 Income tax expense (benefit) (2,737
Slide 13: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS – Pro Forma
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS – Pro Forma Pro Forma Pro Forma Three months ended Twelve months ended May 31, May 31, May 31, May 31, Amounts in thousands 2019 2018 2019 2018 (unaudited) (unaudited) Net income $ 2,753 $ (2,483) $ (11,146) $ (6,227) Income tax expense (be
Slide 14: Growth through Focus Execution Accountability
Growth through Focus Execution Accountability 14